Ulcer

Herbal medicinal product: MyrrhaArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Ethanol, Ulcer, Inflammation, Patient, Monograph, Committee, Boil, Herbal medicine, Date, Skin, Irritation, Commiphora, Medicine, Medicinal plants

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of myrrh.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing myrrh.
  • Herbal medicines containing this myrrh preparation are usually available in liquid forms to be applied to the skin or the lining of the mouth.
  • Myrrh preparations may also be found in combination with other herbal substances in some herbal medicines.

Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections

Retrieved on: 
Tuesday, February 27, 2024
Diabetes, Infection, Ankle, Principal, Ulcer, Quality of life, Clinical trial, Foot, Ambulatory care, RCE, Amputation, Safety, ASX, Liverpool Hospital, DFI, Patient, Data analysis, DFU, Phase, Pharmaceutical industry

The objective of this trial is to evaluate R327’s potential as a topical broad-spectrum anti-infective treatment.

Key Points: 
  • The objective of this trial is to evaluate R327’s potential as a topical broad-spectrum anti-infective treatment.
  • In the coming months, additional study sites both locally and overseas will become active and include the broader patient population in the study.
  • Of the estimated 537 million people worldwide who have diabetes, 19–34% will develop a DFU in their lifetime.
  • “A non-invasive method to treat the burdensome challenges of diabetic foot ulcer infections gives hope to better patient outcomes and avoid limb amputation, as is so commonly the case with these complicated patients.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Tuesday, February 27, 2024
SAN, Ulcerative colitis, Quarter, Week, CDAI, Peripheral, Blood, Obesity, ALS, Research and development, Cryopyrin-associated periodic syndrome, NLRP3, Volunteering, Inflammation, Modulation, Multiple sclerosis, Rheumatology, Safety, UC, CAPS, CNS, Administration, Pharmacokinetics, Patient, TYK2, FCAS, G&A, Ulcer, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $252.2 million as of December 31, 2023.
  • Research and Development (R&D) expenses: R&D expenses were $42.0 million for the fourth quarter of 2023, compared to $30.2 million for the fourth quarter of 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the fourth quarter of 2023, compared to $8.4 million for the fourth quarter of 2022.
  • Net loss: Net loss was $46.8 million for the fourth quarter of 2023, compared to $35.2 million for the fourth quarter of 2022.

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

Retrieved on: 
Monday, February 26, 2024
Incidence, PAR, Doctor of Philosophy, Aes, RV1, MD, Ulcer, Hospital, Standard of care, Amputation, Death, Patient, United, SALSA, Tissue, SOC, Pharmaceutical industry

Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone.

Key Points: 
  • Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care (SOC) or the SOC alone.
  • The primary endpoint is the incidence of DFUs closed at 12 weeks.
  • COVER DFUS II is a pivotal study that PolarityTE will conduct under its open IND for SkinTE.
  • We are excited to evaluate how the optimized healthy cells from the patient in SkinTE can facilitate closure in these difficult-to-treat ulcers.

Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600

Retrieved on: 
Monday, February 26, 2024
SAN, Ulcerative colitis, SAD, MD, Volunteering, Safety, Therapy, Pharmacokinetics, Patient, Ulcer, Trial of the century, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of the single-ascending dose (SAD) cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination consisting of the orally administered NaviCap™ device which delivers a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of the single-ascending dose (SAD) cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.
  • “Completion of the SAD cohorts of the clinical study is an exciting step advancing clinical development for BT-600, and we are pleased with the execution of the study and its progress so far,” said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics.
  • The study, which is being conducted in the United States, consists of two parts.
  • The first is a single-dose ascending cohort comprised of 24 participants receiving BT-600 with tofacitinib at 5 mg and 10 mg doses or placebo.

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid

Retrieved on: 
Tuesday, February 20, 2024
Research Triangle Park, Triangle Park (Quezon City), FDA, Part, Vein, Leg, Skin, Conference, Veterans' affairs, Safety, Therapy, Patent, Part 1, Patient, PST, Clinical trial, Ulcer, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.
  • The study consented 12 patients who were assessed for eligibility to receive the investigational drug treatment.
  • Preliminary data indicate an 84% average reduction in ulcer surface area for the 9 patients completing the 12-week study.
  • These data are being analyzed by the Merakris scientific team and an independent data safety and monitoring committee and will inform the design of Part 2 of the multi-center clinical study.

Foot and Ankle Orthopaedic Surgeons Can Fill the Gap in Barriers to Care for Diabetic Patients

Retrieved on: 
Monday, February 19, 2024
Diabetes, American Diabetes Association, Infection, Ankle, MD, Diabetic foot ulcer, Education, Ulcer, Foot, Surgeon, Risk, Amputation, Hartford, Connecticut, Deformity, Patient, Aronow, Presser foot, DRS, Dentistry

Rosemont, Ill., Feb. 19, 2024 (GLOBE NEWSWIRE) -- Foot and ankle orthopaedic surgeons can help fill the gap in barriers to access to diabetic foot care, according to survey results and presentations at the American Orthopaedic Foot and Ankle Society’s (AOFAS) Winter Meeting last month in Tampa, Florida.

Key Points: 
  • Rosemont, Ill., Feb. 19, 2024 (GLOBE NEWSWIRE) -- Foot and ankle orthopaedic surgeons can help fill the gap in barriers to access to diabetic foot care, according to survey results and presentations at the American Orthopaedic Foot and Ankle Society’s (AOFAS) Winter Meeting last month in Tampa, Florida.
  • The survey results discredited misconceptions that some healthcare professionals and the public may have that orthopaedic surgeons are unable or unwilling to treat diabetic foot diseases.
  • “Foot and ankle orthopaedic surgeons have the expertise and training to treat diabetic foot disease,” Dr. Aronow said.
  • Visit FootCareMD.org to learn more about foot and ankle orthopaedic surgeons and to find one in your area.

Herbal medicinal product: Calendulae flosArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024
Allergy, European Commission, Committee, Monograph, Calendula, Asteraceae, Inflammation, Flower, Plant, Skin, Date, Olive oil, Civil service commission, Patient, Sunburn, Medicine, Ulcer, Community, Herbal medicine, Ethanol, Medicinal plants

Herbal medicinal product: Calendulae flosArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Calendulae flosArray, C: ongoing call for scientific data

How Cinesteam® Helps Manage Smells From Diabetic Foot

Retrieved on: 
Thursday, February 29, 2024
Diabetes, Smell, Blood, Diabetic foot, Sensation, Pain, Infection, Foot, Diabetic neuropathy, Ulcer, Blister, Mayo Clinic, Peripheral neuropathy, Hypoesthesia, Business, Code, Dentistry

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes. The condition can lead to chronic wounds that produce highly unpleasant smells. Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes.
  • Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.
  • The medical condition comes with many health concerns, one of which is commonly referred to as "diabetic foot."
  • Mayo Clinic reports that as much as 50% of those with diabetes can be affected by diabetic neuropathy, opening the doors for diabetic foot to develop.

FutureBridge Report Highlights Evolving Opportunities and Innovation Dynamics in Woundcare

Retrieved on: 
Tuesday, February 27, 2024
Caregiver, Hematoma, Intelligence, Diabetic foot, TPP, Akshi, Abrasion, History, Radiation, Medtech, Patient, Wound, Ulcer, Trauma, Consultant, Pressure, Wound healing

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, has launched its latest report, "Evolving Opportunities and Innovation Dynamics in Woundcare."

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- FutureBridge, a leading techno-commercial consulting and advisory company, has launched its latest report, "Evolving Opportunities and Innovation Dynamics in Woundcare."
  • The comprehensive wound care report highlights these challenges, exploring critical areas like infection prevention, delayed wound healing, and compromised tissue composition.
  • "AI/ML algorithms-based products, smart wearable dressings, novel personalized biological therapies and collaborative innovation are set to disrupt the woundcare space.
  • FutureBridge invites you to explore the full report to gain profound insights into the future of wound care.